13F Holdings
中文EN

FTRE Fortrea Holdings Inc.

Services-Medical Laboratories · Nasdaq · SEC CIK 1965040 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-3.4%
TTM net income YoY93.2%
TTM EPS YoY94.1%
Revenue 3-yr CAGR-2.7%
Net income 3-yr CAGR—

Margins

Gross margin20.0%
Operating margin0.5%
Net margin-2.6%
FCF margin6.3%
EBITDA margin3.4%

Returns

ROE-12.3%
ROA-2.5%
ROIC (approx.)0.7%
Asset turnover0.97x

Leverage & solvency

Liabilities / assets80.6%
Debt / equity1.98x
Current ratio0.97x
Interest coverage—

Cash quality & payout

Operating cash flow / net income-2.94x
Accruals ratio-9.9%
Payout ratio—
Capex / revenue1.2%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$2.72B$2.70B$2.84B$2.84B$3.06B
Cost of revenue$2.22B$2.16B$2.25B$2.11B$2.45B
Gross profit$503.80M$534.20M$590.60M$724.40M$604.40M
SG&A expense$456.40M$560.70M$448.10M$416.10M$303.10M
Operating income-$872.60M-$161.90M$32.00M$187.10M$114.30M
Interest expense——$100,000$200,000$200,000
Pretax income-$983.00M-$275.00M-$30.50M$187.00M$136.40M
Income tax$3.20M-$3.50M$1.20M$41.10M$38.40M
Net income-$986.20M-$328.50M-$25.20M$186.20M$98.00M
EBITDA-$794.60M-$75.00M$130.00M$280.70M$280.60M
EPS (basic)-10.81-3.67-0.292.091.10
EPS (diluted)-10.81-3.67-0.292.091.10
Weighted avg. shares (diluted)—89.50M88.80M88.80M88.80M
Banking
Net interest income——-$69.70M-$200,000—
Balance sheet
Cash & equivalents$174.60M$118.50M$108.60M$110.40M$94.60M
Current assets$897.20M$948.20M$1.25B$1.25B—
PP&E, net———$164.90M—
Goodwill$960.00M$1.71B$1.74B$1.71B$2.08B
Intangibles$622.00M$655.70M$728.10M$823.30M—
Total assets$2.72B$3.58B$4.33B$4.29B—
Current liabilities$913.30M$949.50M$778.40M$699.00M—
Short-term debt$4.80M$74.80M$26.10M$0—
Long-term debt$1.05B$1.05B$1.57B$0—
Total debt$1.05B$1.12B$1.59B$0—
Total liabilities$2.15B$2.22B$2.62B$945.30M—
Shareholders' equity$563.50M$1.36B$1.71B$3.34B$3.26B
Net debt$878.20M$1.01B$1.48B-$110.40M—
Shares outstanding93.10M89.70M88.80M0—
Cash flow statement
Operating cash flow$113.50M$262.80M$168.40M$82.70M$169.80M
Capital expenditure$25.20M$25.50M$40.30M$54.40M$26.50M
Free cash flow$88.30M$237.30M$128.10M$28.30M$143.30M
Investing cash flow$14.40M$251.60M-$31.80M-$54.00M-$26.20M
Financing cash flow-$76.30M-$497.80M-$140.80M-$6.30M-$128.50M
Depreciation & amortization$78.00M$86.90M$98.00M$93.60M$166.30M
Stock-based compensation$74.40M$58.40M$42.70M$25.40M$27.50M

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.